Estrella Immunopharma Q3 2026 Results: Net Loss of $7.38M, Loss Widens
Estrella Immunopharma reported a net loss of $11.98 million for the nine months ended September 30, 2026, compared to $12.45 million in the prior year period. The company's cash position decreased significantly to $92,458, while total stockholders' deficit widened to $13.97 million as research and development expenses remained the primary driver of operating costs.
- Key figure
- Net loss $7.38M